2024
ARID1A in Gynecologic Precancers and Cancers
Morgan J, Jaferi N, Shonibare Z, Huang G. ARID1A in Gynecologic Precancers and Cancers. Reproductive Sciences 2024, 31: 2150-2162. PMID: 38740655, DOI: 10.1007/s43032-024-01585-w.Peer-Reviewed Original ResearchARID1A alterationsGynecologic cancerTumor suppressor ARID1AResponse to chemotherapeutic agentsFrequency of genetic alterationsLoss-of-function mutationsSWI/SNF complex subunitsFemale reproductive tractFunction of ARID1ARadiation therapyTumor-suppressive actionAtypical hyperplasiaARID1A mutationsARID1A deficiencyTherapeutic vulnerabilitiesChemotherapeutic agentsGenetic alterationsImmune modulationClinical evidenceARID1ASignaling pathway interactionsSuppressive actionEndoplasmic reticulumProtein expressionCancer
2011
Phase II trial of adjuvant pelvic radiation “sandwiched” between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma
Einstein MH, Frimer M, Kuo D, Reimers LL, Mehta K, Mutyala S, Huang GS, Hou JY, Goldberg GL. Phase II trial of adjuvant pelvic radiation “sandwiched” between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma. Gynecologic Oncology 2011, 124: 21-25. PMID: 22035806, PMCID: PMC3681611, DOI: 10.1016/j.ygyno.2011.10.007.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBrachytherapyCarboplatinCarcinoma, PapillaryCystadenocarcinoma, SerousDose Fractionation, RadiationDrug Administration ScheduleFemaleHumansMiddle AgedNeoplasm StagingPaclitaxelRadiotherapy, AdjuvantUterine NeoplasmsConceptsAdjuvant pelvic radiationCycles of paclitaxelCycles of chemotherapyRadiation therapyPelvic radiationCarboplatin chemotherapyUterine papillary serous carcinomaExtra-uterine diseaseModality adjuvant therapyNon-hematologic toxicitiesPrescribed radiation therapyVisible residual diseasePhase II trialKaplan-Meier methodPapillary serous carcinomaStage 3Stage 1Combination paclitaxelOverall PFSAdjuvant therapyChemotherapy cyclesII trialMedian ageResidual diseaseSerous carcinoma